Beylerli, Ozal,
Ju, Jiaming,
Beilerli, Aferin,
Gareev, Ilgiz,
Shumadalova, Alina,
Ilyasova, Tatiana,
Bai, Yunlong,
Yang, Baofeng (2023) and may lead to postoperative
recurrence, limiting the clinical benefits to some extent. Therefore, in
Zhiyong, Ji,
Yeping, Ling,
Pingbo, Chen,
Meng, Yuxiao,
Xu, Shancai,
Wu, Pei,
Wang, Chunlei,
Ilyasova, Tatiana,
Sun, Bowen,
Shi, Huaizhang (2023) of
recurrent
serious ischemic events despite standard medical therapy, has been clinically
challenging. A
Buzaev, Igor V.,
Galimova, Rezida M.,
Nabiullina, Dinara I.,
Illarioshkin, Sergey N.,
Zagidullin, Naufal Sh.,
Safin, Shamil M. (2023) = 0.003). The 1-year
recurrence rate was 40% (proctor group) and 17.5% (solo group) (p = 0